SLAMF8 is a structurally distinct SLAM family receptor predominantly expressed in myeloid cells that modulates both innate and adaptive immune responses through noncanonical signaling pathways. It regulates macrophage polarization, oxidative burst, phagocytosis, and cellular trafficking, influencing immune cell development and antigen presentation. SLAMF8 serves as a key regulator of plasmacytoid dendritic cell maturation and cytokine production during intracellular bacterial infection, signaling through NF-κB, IRF7, and STAT-1 1. In antiphospholipid syndrome, SLAMF8 overexpression drives thrombosis and inflammation via the TREM1/TLR4/NF-κB axis 2, while in Alzheimer's disease, elevated SLAMF8 promotes neuroinflammation and oxidative stress through interaction with NINJ2 in the TLR4/NF-κB pathway 3. SLAMF8 dysregulation is implicated in genetic immunodeficiency disorders, as a likely causal negative regulator of inflammation in inflammatory bowel disease 4. Clinically, SLAMF8 emerges as an immunotherapeutic target in cancer: in colorectal cancer, macrophage-specific SLAMF8 promotes M2 polarization and immunosuppression through PI3K/AKT and JAK/STAT3 pathways, whereas SLAMF8 inhibition restores CD8+ T cell antitumor immunity 5. In gastric cancer, high SLAMF8 predicts favorable immunotherapy response to PD-1 blockade with sintilimab 6, and in prostate cancer, SLAMF8 overexpression correlates with poor distant metastasis-free survival through TLR4/NF-κB signaling 7. SLAMF8 inhibition represents a promising strategy for combined immunotherapy across solid tumors.